ELSEVIER

Journal of Controlled Release 41 (1996) 299–300

journal of controlled release

Author Index Volume 41 (1996)

Aungst, B.J., Saitoh, H., Burcham, D.L., Huang, S.-M., Mousa, S.A. and Hussain, M.A., Enhancement of the intestinal absorption of peptides and non-peptides (41) 19
Barry, B.W., see Stott, P.W. (41) 215
Bennett, C.F., Zuckerman, J.E., Kornbrust, D., Sasmor, H., Leeds, J.M. and Crooke, S.T., Pharmacokinetics in mice of a [^{3}H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid (41) 121
Bijsterbosch, M.K., see Van Berkel, T.J.C. (41) 85
Boddé, H.E., see Hoogstraate, A.J. (41) 77
Boddé, H.E., see Van der Geest, R. (41) 205
Bonina, F.P., Montenegro, L., De Caprariis, P., Palagiano, F., Capasso, A. and Sorrentino, L., Pharmacokinetic and pharmacodynamic profile of triethylene glycol indomethacin ester as a new oral prodrug (41) 187
Borchardt, R.T., see Pauletti, G.M. (41) 3
Brain, K.R., see Harrison, J.E. (41) 283
Breimer, D.D., see Verhoef, J.C. (41) 1
Burcham, D.L., see Aungst, B.J. (41) 19
Capasso, A., see Bonina, F.P. (41) 187
Cavallaro, G., see Giammona, G. (41) 195
Chen, K.-S., see Lin, Y.-Y. (41) 163
Chien, Y.W., see Ye, W.-P. (41) 259
Cleland, J.L., see Jones, A.J.S. (42) 147
Compans, R.W., see Duncan, J.D. (41) 237
Corradin, G., see Thomasin, C. (41) 131
Crooke, S.T., see Bennett, C.F. (41) 121
Danhof, M., see Van der Geest, R. (41) 205
De Caprariis, P., see Bonina, F.P. (41) 187
DeLuca, P.P., see Mehta, R.C. (41) 249
Duncan, J.D., Wang, P.X., Harrington, C.M., Schafer, D.P., Matsuoka, Y., Mestecky, J.F., Compans, R.W. and Novak, M.J., Comparative analysis of oral delivery systems for live rotavirus vaccines (41) 237
Elshove, D.A.R., see Van der Geest, R. (41) 205
Florence, A.T., see Hillery, A.M. (41) 271
Fujita, T., see Yamamoto, A. (41) 57
Gander, B., see Thomasin, C. (41) 131
Gangwar, S., see Pauletti, G.M. (41) 3
Giammona, G., Pitarresi, G., Tomarchio, V., Cavallaro, G. and Mineo, M., Crosslinked α,β-polyasparthydrazide hydrogels: effect of crosslinking degree and loading method on cytarabine release rate (41) 195
Green, P.G., Iontophoretic delivery of peptide drugs (41) 33
Gregoriadis, G., Gursel, I., Gursel, M. and McCormack, B., Liposomes as immunological adjuvants and vaccine carriers (41) 49
Groundwater, P.W., see Harrison, J.E. (41) 283
Gursel, I., see Gregoriadis, G. (41) 49
Gursel, M., see Gregoriadis, G. (41) 49
Hadgraft, J., see Harrison, J.E. (41) 283
Haglund, B.O., Joshi, R. and Himmelstein, K.J., An in situ gelling system for parenteral delivery (41) 229
Harrington, C.M., see Duncan, J.D. (41) 237
Harrison, J.E., Groundwater, P.W., Brain, K.R. and Hadgraft, J., Azone® induced fluidity in human stratum corneum. A fourier transform infrared spectroscopy investigation using the per-deuterated analogue (41) 283
Hashida, M., Mahato, R.I., Kawabata, K., Miyao, T., Nishikawa, M. and Takakura, Y., Pharmacokinetics and targeted delivery of proteins and genes (41) 91
Hillery, A.M., Toth, I., Shaw, A.J. and Florence, A.T., Co-polymerised peptide particles (CPP) I: synthesis, characterisation and in vitro studies on a novel oral nanoparticulate delivery system (41) 271
Himmelstein, K.J., see Haglund, B.O. (41) 229
Hoogstraate, A.J., Verhoef, J.C., Tuk, B., Pijpers, A., Van Leengoed, L.A.M.G., Verheijden, J.H.M., Junginger, H.E. and Boddé, H.E., Buccal delivery of fluorescein isothiocyanate-dextran 4400 and the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs (41) 77
Huang, S.-M., see Aungst, B.J. (41) 19
Hussain, M.A., see Aungst, B.J. (41) 19
Jones, A.J.S. and Cleland, J.L., Technical and regulatory hurdles in delivery aspects of macromolecular drugs (42) 147
Joshi, R., see Haglund, B.O. (41) 229
Junginger, H.E., see Hoogstraate, A.J. (41) 77
Kataoka, K., see Koyama, Y. (41) 171
Kawabata, K., see Hashida, M. (41) 91
Kawaide, A., see Koyama, Y. (41) 171
Knipp, G.T., see Pauletti, G.M. (41) 3
Kontturi, K. and Murtomäki, L., Mechanistic model for transdermal transport including iontophoresis (41) 177
Kornbrust, D., see Bennett, C.F. (41) 121
Koyama, Y., Miyagawa, T., Kawaide, A. and Kataoka, K., Receptor-mediated absorption of high molecular weight dextrans from intestinal tract (41) 171
Lavrijsen, A.P.M., see Van der Geest, R. (41) 205

Leeds, J.M., see Bennett, C.F. (41) 121
Lin, S.-Y., see Lin, Y.-Y. (41) 163
Lin, Y.-Y., Chen, K.-S. and Lin, S.-Y., Development and investigation of a thermo-responsive cholesteryl oleyl carbonate-embedded membrane (41) 163
Mahato, R.I., see Hashida, M. (41) 91
Matsuoka, Y., see Duncan, J.D. (41) 237
McCormack, B., see Gregoriadis, G. (41) 49
Mehta, R.C., Thanoo, B.C. and DeLuca, P.P., Peptide containing microspheres from low molecular weight and hydrophilic poly(*d*,*l*-lactide-co-glycolide) (41) 249
Men, Y., see Thomasin, C. (41) 131
Merkle, H.P., see Thomasin, C. (41) 131
Merkus, F.W.H.M., Schipper, N.G.M. and Verhoef, J.C., The influence of absorption enhancers on intranasal insulin absorption in normal and diabetic subjects (41) 69
Mestecky, J.F., see Duncan, J.D. (41) 237
Mineo, M., see Giammona, G. (41) 195
Miyagawa, T., see Koyama, Y. (41) 171
Miyao, T., see Hashida, M. (41) 91
Montenegro, L., see Bonina, F.P. (41) 187
Mousa, S.A., see Aungst, B.J. (41) 19
Muranishi, S., see Yamamoto, A. (41) 57
Murtomäki, L., see Kontturi, K. (41) 177
Nerurkar, M.M., see Pauletti, G.M. (41) 3
Nishikawa, M., see Hashida, M. (41) 91
Novak, M.J., see Duncan, J.D. (41) 237
Okumu, F.W., see Pauletti, G.M. (41) 3
Palagiano, F., see Bonina, F.P. (41) 187
Pauletti, G.M., Gangwar, S., Knipp, G.T., Nerurkar, M.M., Okumu, F.W., Tamura, K., Siahaan, T.J. and Borchardt, R.T., Structural requirements for intestinal absorption of peptide drugs (41) 3
Pijpers, A., see Hoogstraate, A.J. (41) 77
Pitarresi, G., see Giammona, G. (41) 195
Pokharkar, V.B. and Sivaram, S., Permeability studies across poly(alkylene carbonate) membranes (41) 157
Rensen, P.C.N., see Van Berkel, T.J.C. (41) 85
Saitoh, H., see Aungst, B.J. (41) 19
Sasmor, H., see Bennett, C.F. (41) 121
Schafer, D.P., see Duncan, J.D. (41) 237
Schipper, N.G.M., see Merkus, F.W.H.M. (41) 69
Shaw, A.J., see Hillery, A.M. (41) 271
Siahaan, T.J., see Pauletti, G.M. (41) 3
Sivaram, S., see Pokharkar, V.B. (41) 157
Sorrentino, L., see Bonina, F.P. (41) 187
Stott, P.W., Williams, A.C. and Barry, B.W., Characterization of complex coacervates of some tricyclic antidepressants and evaluation of their potential for enhancing transdermal flux (41) 215
Szoka, Jr., F.C., see Zelphati, O. (41) 99
Takakura, Y., see Hashida, M. (41) 91
Tamura, K., see Pauletti, G.M. (41) 3
Thanoo, B.C., see Mehta, R.C. (41) 249
Thomasin, C., Corradin, G., Men, Y., Merkle, H.P. and Gander, B., Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response (41) 131
Tomarchio, V., see Giammona, G. (41) 195
Toth, I., see Hillery, A.M. (41) 271
Tuk, B., see Hoogstraate, A.J. (41) 77
Van Berkel, T.J.C., Van Dijk, M.C.M., Bijsterbosch, M.K. and Rensen, P.C.N., Drug targeting by neo-lipoproteins (41) 85
Van der Geest, R., Elshove, D.A.R., Danhof, M., Lavrijsen, A.P.M. and Boddé, H.E., Non-invasive assessment of skin barrier integrity and skin irritation following iontophoretic current application in humans (41) 205
Van Dijk, M.C.M.., see Van Berkel, T.J.C. (41) 85
Van Leengoed, L.A.M.G., see Hoogstraate, A.J. (41) 77
Verheijden, J.H.M., see Hoogstraate, A.J. (41) 77
Verhoef, J.C. and Breimer, D.D., Guest Editorial (41) 1
Verhoef, J.C., see Hoogstraate, A.J. (41) 77
Verhoef, J.C., see Merkus, F.W.H.M. (41) 69
Wang, P.X., see Duncan, J.D. (41) 237
Williams, A.C., see Stott, P.W. (41) 215
Yamamoto, A., Fujita, T. and Muranishi, S., Pulmonary absorption enhancement of peptides by absorption enhancers and protease inhibitors (41) 57
Ye, W.-P. and Chien, Y.W., Dual-controlled drug delivery across biodegradable copolymer. II. Delivery kinetics of levonorgestrel and estradiol from (matrix/matrix) laminate drug delivery system (41) 259
Zelphati, O. and Szoka, Jr., F.C., Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet? (41) 99
Zuckerman, J.E., see Bennett, C.F. (41) 121

ELSEVIER

Journal of Controlled Release 41 (1996) 301–302

journal of controlled release

Subject Index Volume 41 (1996)

Absorption enhancers, (41) 57, (41) 69
Antigen release, (41) 131
Antigens, (41) 49
Antisense oligonucleotide, (41) 121
Antisense oligonucleotides, (41) 99
Aqueous pores, (41) 177
Azone, (41) 283
Barrier function, (41) 205
Bile salts, (41) 77, (41) 215
Bioavailability, (41) 19
Biodegradable microspheres, (41) 131
Buccal administration, (41) 77
Buserelin, (41) 77
Caprolactone and lactide block copolymer, (41) 259
Carboxyl number, (41) 249
Cationic lipid, (41) 121
Cationic liposomes, (41) 91
Cellular uptake, (41) 99
Cellulose nitrate membrane, (41) 163
Chemical modification, (41) 91
Cholesteryl oleyl carbonate, (41) 163
Clinical evaluation, (42) 147
Complex coacervation, (41) 215
Co-polymeric particles, (41) 271
Cytarabine, (41) 195
Delivery systems, (42) 147
Desorption, (41) 177
Dextran, (41) 171
Diffusivity, (41) 157
Drug delivery, (41) 33, (41) 99, (41) 229
Dual-controlled delivery, (41) 259
Efficacy, (41) 69
Electrotransport, (41) 33
Emulsions, (41) 85
Enhancement, (41) 19
Estradiol, (41) 259
Fluorescein isothiocyanate-labelled dextran 4400, (41) 77
Fourier transform infrared spectroscopy, (41) 283
Glass transition temperature, (41) 249
Glucose-transporter, (41) 171
Glutaraldehyde, (41) 195
Hepatitis B, (41) 85
Human, (41) 205
Hydrogels, (41) 195
Hydrophilic PLGA, (41) 249
Immune response, (41) 49
Immune responses, (41) 131
Immunological adjuvant, (41) 49
Implant, (41) 259
Indomethacin, (41) 187
Insulin, (41) 69
Interleukins, (41) 49
Intestinal absorption, (41) 171
Intestinal barrier functions, (41) 3
Intestinal permeation, (41) 19
Intracellular distribution, (41) 99
In-vivo, (41) 205
Iontophoresis, (41) 33, (41) 177, (41) 205
Irritation, (41) 205
Levonorgestrel, (41) 259
Liposome, (41) 121
Liposomes, (41) 49, (41) 99
Luteinizing hormone, (41) 271
Macromolecular pharmaceuticals, (42) 147
(Matrix/matrix) laminate drug delivery system, (41) 259
Microspheres, (41) 237
Nanoparticles, (41) 271
Nasal delivery, (41) 69
Neo-high density lipoprotein, (41) 85
Non-pareil seeds, (41) 237
Oral absorption, (41) 19
Oral delivery systems, (41) 237
Oral drug delivery, (41) 271
Oral prodrugs, (41) 187
Oral vaccination, (41) 237
Particle size analysis, (41) 215
Penetration enhancer, (41) 283
Peptidase inhibitors, (41) 3
Peptide delivery, (41) 3
Peptide microspheres, (41) 249
Peptide modifications, (41) 3
Peptide, (41) 33
Peptides, (41) 57
Perdeuterated, (41) 283
Permeability coefficient, (41) 157
Permeability vs. partition, (41) 177
Pharmacodynamic, (41) 187
Pharmacokinetic, (41) 187

Pharmacokinetics, (41) 91, (41) 121
Piroxicam, (41) 157
Polyacrylic acid/PAA, (41) 229
Poly(alkylene carbonate), (41) 157
α,β-Polyasparthydrazide, (41) 195
Poly(lactide) (PLA), (41) 131
Poly(lactide-co-glycolide) (PLGA), (41) 131
Polyethylene glycol/PEG, (41) 229
Polymer complex, (41) 229
Polymer degradation, (41) 131
Polymethacrylic acid/PMA, (41) 229
Prodrugs, (41) 3
Prolonged release, (41) 195
Protease inhibitors, (41) 57
Protein and gene targeting, (41) 91
Pulmonary absorption, (41) 57
Receptor-mediated endocytosis, (41) 91
Recombinant chylomicrons, (41) 85
Releasing hormone, (41) 271
Rotavirus, (41) 237
Safety, (41) 69
Stability, (41) 57
Stratum corneum lipids, (41) 283
Swellable micromatrices, (41) 195
Synthetic malaria antigen, (41) 131
Tableting, (41) 237
Targeting, (41) 85
Tetanus toxoid, (41) 131
Theophylline, (41) 157
Thermal stimulus response, (41) 163
Transdermal, (41) 33, (41) 205
Transdermal permeation, (41) 215
Transdermal transfer, (41) 177
Tricyclic antidepressants, (41) 215
Triethylene glycol, (41) 187
Vaccines, (41) 49